GSK/Corixa Bexxar cmte. review?
Executive Summary
GlaxoSmithKline/Corixa's Bexxar (tositumomab) is slated for review for treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma by FDA's Oncologic Drugs Advisory Committee at the tentatively scheduled Dec. 17-18 meeting. Corixa requested committee review of the drug in its appeal of a March 12 "complete response" letter (1"The Pink Sheet" May 20, In Brief). The company has said it expected a review of Bexxar before year-end (2"The Pink Sheet" Aug. 12, In Brief)...